Becton, Dickinson and Company $BDX Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,075,633 shares of the medical instruments supplier’s stock after acquiring an additional 77,603 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $201,326,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Activest Wealth Management lifted its stake in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares during the period. SOA Wealth Advisors LLC. raised its holdings in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the period. Cornerstone Planning Group LLC lifted its position in Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 139 shares during the period. Finally, Grey Fox Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company in the third quarter valued at $32,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent research reports. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Piper Sandler boosted their price target on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a report on Wednesday, January 28th. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Bank of America lifted their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $213.36.

Becton, Dickinson and Company Stock Down 0.7%

NYSE BDX opened at $206.41 on Friday. The business has a fifty day moving average price of $199.50 and a 200 day moving average price of $191.98. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market cap of $58.81 billion, a P/E ratio of 35.41, a P/E/G ratio of 2.30 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $239.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business posted $3.81 earnings per share. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Becton, Dickinson and Company announced that its board has initiated a share repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 2,463 shares of company stock valued at $501,530 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.